Market Access/ News/ News Orphazyme ‘looking at options’ after lead drug hits buffers in EU Phil Taylor Niemann-Pick type C, Orphazyme, Rare diseases 0 Comment Orphazyme’s hopes of getting EU approval for its Niemann-Pick disease type C (NPC) therapy arimoclomol after a rejection Share X Orphazyme ‘looking at options’ after lead drug hits buffers in EU https://pharmaphorum.com/news/orphazyme-looking-at-options-after-lead-drug-hits-buffers-in-eu/
